- Home
- ACHV vs TARA Comparison
ACHV vs TARA Comparison
Compare ACHV & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACHV | TARA |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.0M | 268.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ACHV | TARA |
|---|---|---|
| Price | $4.22 | $6.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $15.50 | ★ $21.00 |
| AVG Volume (30 Days) | 828.7K | ★ 1.2M |
| Earning Date | 03-10-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.84 | $2.77 |
| 52 Week High | $6.03 | $7.82 |
Technical Indicators
Market Signals| Indicator | ACHV | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 34.31 | 60.38 |
| Support Level | $4.05 | $6.85 |
| Resistance Level | $4.49 | $7.33 |
| Average True Range (ATR) | 0.34 | 0.46 |
| MACD | -0.18 | 0.14 |
| Stochastic Oscillator | 5.82 | 74.13 |
Price Performance
Historical ComparisonAbout ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).